Healthy Skepticism Library item: 4897

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Shatin D, Gardner JS, Stergachis A, Blough D, Graham D.
Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants.
Pharmacoepidemiol Drug Saf 2005 Mar; 14:(3):149-54
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3058&uid=15386714&db=PubMed&url=http://dx.doi.org/10.1002/pds.961

Abstract:

PURPOSE: An evaluation was made of the effectiveness in changing prescribing behavior of ‘Dear Health Professional (DHP)’ letters mailed by the manufacturer to physicians and other health professionals advising them of safety information on co-prescribing of tramadol and antidepressants. METHODS: A retrospective cohort analysis of prescription claims of all plan members from 12 UnitedHealth Group-affiliated health plans who received a first prescription for tramadol between 1 April 1995 and 31 December 1996. The prevalence of co-prescribing of antidepressants and tramadol relative to the date of the ‘DHP’ communication was determined. RESULTS: 9218 plan members received an initial prescription for tramadol within the observation period. Prior to the date of the ‘DHP’ communication 1061/4774 (22.2%) members received a prescription for an antidepressant within 30 days of their first prescription for tramadol. Following the date of the communication 844/4444 (19.0%) of members received an antidepressant within 30 days of their first prescription for tramadol. An overall decreasing linear trend in antidepressant co-prescribing was evident over the observation period, but there was no statistically significant acceleration in the decrease following this communication. CONCLUSIONS: The mailed ‘DHP’ advisory letter did not affect the rate of co-prescribing of tramadol with antidepressants. Copyright 2004 John Wiley & Sons, Ltd.

Keywords:
Adult Analgesics, Opioid/adverse effects Analgesics, Opioid/therapeutic use Antidepressive Agents/adverse effects* Antidepressive Agents/therapeutic use Cohort Studies Drug Industry/methods Drug Industry/statistics & numerical data Drug Therapy, Combination Drug Utilization Review/methods Drug Utilization Review/statistics & numerical data Humans Information Dissemination/methods* Insurance, Pharmaceutical Services/statistics & numerical data Physician's Practice Patterns Prescriptions, Drug/statistics & numerical data Research Support, U.S. Gov't, Non-P.H.S. Retrospective Studies Time Factors Tramadol/adverse effects* Tramadol/therapeutic use